Dr Liz Dallimore on the exciting times ahead for Argenica Therapeutics as they fast track Phase 2
MAKING MONEY MATTER: Biotech companies have not been top of investors minds recently but I was excited to speak with Dr Liz Dallimore of Argenica Therapeutics (ASX:AGN) who are moving from Phase 1 to Phase 2 trials. Since we last spoke there has been a steady increase in the share price as they work on a drug to reduce brain damage after strokes as well as other brain injuries.TIME STAMPS:00:00 intro02:00 Background to Argenica Therapeutics (asx:AGN) and what sets them apart04:30 Phase 1 and Phase 2 trials and the outcomes from the trials06:50 The competition08:30 The recent placement and use of funds going forward12:00 The importance of the FDA approval and the market in the USA14:30 Timelines for the phase 2 trials and any challenges?18:00 Progress with the FDA21:00 Current valuation and milestones ahead and future partners23:30 The other applications for the company going forward26:30 Three reasons to sit up and take notice right now
Dr Liz Dallimore on the exciting times ahead for Argenica...
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
79.0¢ |
Change
0.010(1.28%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 78.0¢ | 80.5¢ | 78.0¢ | $71.40K | 90.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 78.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 80.5¢ | 2444 | 1 |
View Market Depth
| Last trade - 15.55pm 23/08/2024 (20 minute delay) ? |
| AGN (ASX) Chart |